Allergy Therapeutics plc – LSE:AGY.L

Allergy Therapeutics stock price today

GBP 32.25
+25.67
+390.12%
Financial Health
0
1
2
3
4
5
6
7
8
9

Allergy Therapeutics stock price monthly change

+17.92%
month

Allergy Therapeutics stock price quarterly change

+17.92%
quarter

Allergy Therapeutics stock price yearly change

+174.17%
year

Allergy Therapeutics key metrics

Market Cap
 285.98M
Enterprise value
 3.96B
P/E
 -3.12
EV/Sales
 50.71
EV/EBITDA
 317.56
Price/Sales
 0.50
Price/Book
 1.03
PEG ratio
 N/A
EPS
 -0.03
Revenue
 117.50M
EBITDA
 -36.73M
Income
 -55.38M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 9.03%
Oper. margin
 10.62%
Gross margin
 74.17%
EBIT margin
 10.62%
EBITDA margin
 -31.27%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Allergy Therapeutics stock price history

Allergy Therapeutics stock forecast

Allergy Therapeutics financial statements

Profit Margin

Allergy Therapeutics plc (LSE:AGY.L): Profit margin
Dec 2021 24.34M 3.33M 13.7%
Dec 2022 39.90M -8.50M -21.32%
Jun 2023 19.68M -34.56M -175.58%
Dec 2023 33.57M -15.65M -46.62%
AGY.L income statement history

Allergy Therapeutics Financials Estimate

Allergy Therapeutics plc (LSE:AGY.L): Analyst Estimates
2026 182.4M 0
2027 258.6M 13.40M 5.18%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Allergy Therapeutics plc (LSE:AGY.L): Debt to assets
Dec 2021 91973000 36.99M 40.23%
Sep 2022 71612000 33.65M 46.99%
Dec 2022 71612000 33.65M 46.99%
Dec 2023 69077000 42.61M 61.69%
AGY.L balance sheet history

Cash Flow

Allergy Therapeutics plc (LSE:AGY.L): Cash Flow
Dec 2021 3.71M -1.23M -1.48M
Dec 2022 -7.57M -2.88M 5.03M
Jun 2023 -23.34M -1.78M 24.87M
Dec 2023 -12.35M -1.86M 12.83M
AGY.L cash flow history

Allergy Therapeutics alternative data

Allergy Therapeutics
Employees

Allergy Therapeutics plc (LSE:AGY.L): Employee count
Aug 2023 622
Sep 2023 622
Oct 2023 622
Nov 2023 622
Dec 2023 622
Jan 2024 622
Feb 2024 612
Mar 2024 612
Apr 2024 612
May 2024 612
Jun 2024 612
Jul 2024 612

Allergy Therapeutics other data

Allergy Therapeutics
Executives

Insider Compensation
Mr. Manuel Llobet (1964) Chief Executive Officer & Executive Director
 $559,220
Mr. Nicolas Alexander Ulrich Wykeman (1965) Chief Financial Officer & Executive Director
 $312,150

Frequently Asked Questions (FAQ)

  • What's the price of Allergy Therapeutics stock today?

    One share of Allergy Therapeutics stock can currently be purchased for approximately $32.25.

  • When is Allergy Therapeutics's next earnings date?

    Unfortunately, Allergy Therapeutics's (AGY.L) next earnings date is currently unknown.

  • Does Allergy Therapeutics pay dividends?

    No, Allergy Therapeutics does not pay dividends.

  • How much money does Allergy Therapeutics make?

    Allergy Therapeutics has a market capitalization of 285.98M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 24.14% to 55.2M US dollars.

  • What is Allergy Therapeutics's stock symbol?

    Allergy Therapeutics plc is traded on the LSE under the ticker symbol "AGY.L".

  • What is Allergy Therapeutics's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Allergy Therapeutics?

    Shares of Allergy Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Allergy Therapeutics's key executives?

    Allergy Therapeutics's management team includes the following people:

    • Mr. Manuel Llobet Chief Executive Officer & Executive Director(age: 61, pay: $559,220)
    • Mr. Nicolas Alexander Ulrich Wykeman Chief Financial Officer & Executive Director(age: 60, pay: $312,150)

  • How many employees does Allergy Therapeutics have?

    As Jul 2024, Allergy Therapeutics employs 612 workers.

  • When Allergy Therapeutics went public?

    Allergy Therapeutics plc is publicly traded company for more then 20 years since IPO on 11 Oct 2004.

  • What is Allergy Therapeutics's official website?

    The official website for Allergy Therapeutics is allergytherapeutics.com.

  • How can i contact Allergy Therapeutics?

    Allergy Therapeutics can be reached via phone at +44 1903 844700.

Allergy Therapeutics company profile:

Allergy Therapeutics plc

allergytherapeutics.com
Exchange:

LSE

Full time employees:

612

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

+44 1903 844700
Dominion Way
Worthing, BN14 8SA

:
ISIN: GB00B02LCQ05
CUSIP: G0236K104